Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome
- 1 March 2004
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 17 (3), 277-287
- https://doi.org/10.1038/modpathol.3800006
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- HER2 Assessment by Immunohistochemical Analysis and Fluorescence In Situ HybridizationAmerican Journal of Clinical Pathology, 2002
- HER-2/neu, P53, and DNA analyses as prognosticators for survival in endometrial carcinomaPublished by Wolters Kluwer Health ,2002
- Aneusomy 17 in Breast Cancer: Its Role in HER-2/neu Protein Expression and Implication for Clinical Assessment of HER-2/neu StatusLaboratory Investigation, 2002
- Defining a Test for HER-2/neu Evaluation in Breast Cancer in the Diagnostic SettingLaboratory Investigation, 2001
- Chromogenic in Situ HybridizationThe American Journal of Pathology, 2000
- Concomitant Oncoprotein Detection with Fluorescence in Situ Hybridization (CODFISH): A Fluorescence-Based Assay Enabling Simultaneous Visualization of Gene Amplification and Encoded Protein ExpressionThe Journal of Molecular Diagnostics, 2000
- MIB-1 in Endometrial Carcinoma: Prognostic Significance with 5-Year Follow-UpGynecologic Oncology, 1999
- Amplification and Expression of the C-erbB-2 Oncogene in Normal, Hyperplastic, and Malignant EndometriaInternational Journal of Gynecological Pathology, 1995
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- The neu Gene: an erb B-Homologous Gene Distinct from and Unlinked to the Gene Encoding the EGF ReceptorScience, 1985